From Earlier: AstraZeneca to Initiate a New Study of BRILINTA (Ticagrelor) in Patients with PAD
AstraZeneca (NYSE: AZN) today announced plans to conduct the EUCLID study, a global clinical trial involving 11,500 patients with peripheral artery disease (PAD), a condition affecting approximately 27 million people in Europe and North America.1 PAD patients are at high risk of myocardial infarction (MI), strokes, and other health complications. EUCLID is designed to evaluate cardiovascular (CV) event rate and safety in PAD patients. Ticagrelor is currently not approved for the treatment of patients with PAD.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.